sacituzumab govitecan + trilaciclib

Sacituzumab govitecan + trilaciclib is a combination regimen under investigation for the treatment of metastatic triple-negative breast cancer (mTNBC). Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (Trop-2), linked to the topoisomerase I inhibitor SN-38. It delivers cytotoxic SN-38 directly to Trop-2–expressing tumor cells, causing DNA damage and cell death. Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor that induces transient G1 cell cycle arrest in hematopoietic stem and progenitor cells when administered prior to chemotherapy or ADCs. This myeloprotective effect reduces chemotherapy-induced myelosuppression and may enhance antitumor immunity by preserving immune function. The combination aims to improve tolerability and efficacy of sacituzumab govitecan by reducing adverse events such as neutropenia, anemia, and diarrhea while potentially enhancing immune-mediated antitumor effects[1][2][3][4].

Brand names

CoselaTrodelvy

Other names

SG + trilaciclib